Eledon Pharmaceuticals, Inc. Share Price
Equities
ELDN
US28617K1016
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.37 USD | +15.05% | +17.33% | +31.67% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 51.12M 4.26B |
---|---|---|---|---|---|
Net income 2024 * | -53M -4.42B | Net income 2025 * | -74M -6.17B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-1.42
x | P/E ratio 2025 * |
-2.29
x | Employees | 20 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 94.57% |
Latest transcript on Eledon Pharmaceuticals, Inc.
1 day | +15.05% | ||
1 week | +17.33% | ||
Current month | +15.05% | ||
1 month | +15.05% | ||
3 months | +27.42% | ||
6 months | +48.67% | ||
Current year | +31.67% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 51 | 01/20/01 | |
Paul Little
DFI | Director of Finance/CFO | 60 | 15/21/15 |
Steven N. Perrin
PSD | President | 59 | 14/20/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Keith Katkin
CHM | Chairman | 52 | 01/17/01 |
Walter C. Ogier
BRD | Director/Board Member | 67 | 14/20/14 |
John S. McBride
BRD | Director/Board Member | 72 | 01/17/01 |
Date | Price | Change | Volume |
---|---|---|---|
29/24/29 | 2.37 | +15.05% | 317,451 |
26/24/26 | 2.06 | +1.98% | 81,544 |
25/24/25 | 2.02 | +2.54% | 67,382 |
24/24/24 | 1.97 | -8.80% | 100,805 |
23/24/23 | 2.16 | +6.93% | 190,023 |
Delayed Quote Nasdaq, April 30, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+31.67% | 51.12M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- ELDN Stock